Effectiveness and cost of multilayered colorectal cancer screening promotion interventions at federally qualified health centers in Washington State

Cancer

Volumn 124, Issue 21, 2018, Pages 4121-4129

  Kemper, Kathryn E ^a   Glaze, Becky L ^a   Eastman, Casey L ^b   Waldron, Roxane C ^b   Hoover, Sonja ^c   Flagg, T’Ronda ^d   Tangka, Florence K L ^d   Subramanian, Sujha ^c  

^a HealthPoint   (United States)

^b WASHINGTON STATE DEPARTMENT OF HEALTH   (United States)

^c RTI INTERNATIONAL   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

cancer screening; colorectal cancer; community health centers; health care economics and organizations; reminder system; Washington

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SCREENING; COLORECTAL CANCER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CENTER; HEALTH PROMOTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICALLY UNDERSERVED; OCCULT BLOOD TEST; PATIENT COMPLIANCE; PRIORITY JOURNAL; TELECONSULTATION; WASHINGTON; ACCREDITATION; COLORECTAL TUMOR; COST BENEFIT ANALYSIS; EARLY CANCER DIAGNOSIS; ECONOMICS; FECES; GOVERNMENT; HEALTH CARE PLANNING; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; ORGANIZATION AND MANAGEMENT; POSTAL MAIL; PROCEDURES; PROGRAM EVALUATION; VERY ELDERLY;

ACCREDITATION; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FECES; FEDERAL GOVERNMENT; FEMALE; HEALTH PLAN IMPLEMENTATION; HEALTH PROMOTION; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; POSTAL SERVICE; PROGRAM EVALUATION; WASHINGTON;

EID: 85055467259     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.31693     Document Type: Article

References (25)

1. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2016;315:2564-2575.
2. Washington State Department of Health. Washington State Cancer Registry. Cancer by Site. Tumwater, WA: Washington State Department of Health; 2014. Available at: https://fortress.wa.gov/doh/wscr/WSCR/PDF/14Report/CancerBySite14.pdf. Accessed February 2, 2018.
3. Washington State Department of Health. Health of Washington State: Colorectal Cancer. Tumwater, WA: Washington State Department of Health; 2013. Available at: https://www.doh.wa.gov/Portals/1/Documents/1500/CD-CCN2013.pdf. Accessed March 31, 2015.
4. US Department of Health and Human Services, Health Resources and Services Administration. 2016 Health Center Data: Washington Program Grantee Data. Rockville, MD: US Department of Health and Human Services. Available at: https://bphc.hrsa.gov/uds/datacenter.aspx?q=d&year=2016&state=WA#glist. Accessed October 3, 2017.
5. White A, Thompson TD, White MC, et al. Cancer screening test use—United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66:201-206.
6. Singal AG, Gupta S, Skinner CS, et al. Effect of colonoscopy outreach vs fecal immunochemical test outreach on colorectal cancer screening completion: a randomized clinical trial. JAMA. 2017;318:806-815.
7. Coronado GD, Vollmer WM, Petrik A, et al. Strategies and opportunities to STOP colon cancer in priority populations: pragmatic pilot study design and outcomes [serial online]. BMC Cancer. 2014;14:55.
8. Coronado GD, Sanchez J, Petrik A, Kapka T, DeVoe J, Green B. Advantages of wordless instructions on how to complete a fecal immunochemical test: lessons from patient advisory council members of a federally qualified health center. J Cancer Educ. 2014;29:86-90.
9. National Colorectal Cancer Roundtable, American Cancer Society. 80% by 2018 Communications Guidebook: Recommended Messaging to Reach the Unscreened. Atlanta, GA: National Colorectal Cancer Roundtable, American Cancer Society; 2017. Available at: https://nccrt.org/resource/2017-80-2018-communications-guidebook-recommended-messaging-reach-unscreened. Accessed April 10, 2018.
10. Subramanian S, Ekwueme DU, Gardner JG, Trogdon J. Developing and testing a cost-assessment tool for cancer screening programs. Am J Prev Med. 2009;37:242-247.
11. Subramanian S, Tangka FK, Hoover S, et al. Costs of planning and implementing the CDC's Colorectal Cancer Screening Demonstration Program. Cancer. 2013;119(suppl 15):2855-2862.
12. Tangka FK, Subramanian S, Bapat B, et al. Cost of starting colorectal cancer screening programs: results from 5 federally funded demonstration programs [serial online]. Prev Chronic Dis. 2008;5:A47.
13. Tangka FK, Subramanian S, Hoover S, et al. Costs of promoting cancer screening: evidence from CDC's Colorectal Cancer Control Program (CRCCP). Eval Program Plann. 2017;62:67-72.
14. Daskalakis C, Vernon SW, Sifri R, et al. The effects of test preference, test access, and navigation on colorectal cancer screening. Cancer Epidemiol Biomarkers Prev. 2014;23:1521-1528.
15. Levy BT, Daly JM, Xu Y, Ely JW. Mailed fecal immunochemical tests plus educational materials to improve colon cancer screening rates in Iowa Research Network (IRENE) practices. Am Board Fam Med. 2012;25:73-82.
16. Potter MB, Phengrasamy L, Hudes ES, McPhee SJ, Walsh JM. Offering annual fecal occult blood tests at annual flu shot clinics increases colorectal cancer screening rates. Ann Fam Med. 2009;7:17-23.
17. Hillyer GC, Basch CE, Schmitt KM, Neugut AI. Feasibility and efficacy of pairing fecal immunochemical testing with mammography for increasing colorectal cancer screening among uninsured Latinas in northern Manhattan. Prev Med. 2011;53:194-198.
18. Kimura A, Sin MK, Spigner C, Tran A, Tu SP. Barriers and facilitators to colorectal cancer screening in Vietnamese Americans: a qualitative analysis. J Cancer Educ. 2014;29:728-734.
19. Arnold CL, Rademaker A, Bailey SC, et al. Literacy barriers to colorectal cancer screening in community clinics. J Health Commun. 2012;17(suppl 3):252-264.
20. Coronado GD, Schneider JL, Sanchez JJ, Petrik AF, Green B. Reasons for non-response to a direct-mailed FIT kit program: lessons learned from a pragmatic colorectal-cancer screening study in a federally sponsored health center. Transl Behav Med. 2015;5:60-67.
21. Jones RM, Devers KJ, Kuzel AJ, Woolf SH. Patient-reported barriers to colorectal cancer screening: a mixed-methods analysis. Am J Prev Med. 2010;38:508-516.
22. Schlichting JA, Mengeling MA, Makki NM, et al. Increasing colorectal cancer screening in an overdue population: participation and cost impacts of adding telephone calls to a FIT mailing program. J Community Health. 2014;39:239-247.
23. Liss DT, French DD, Buchanan DR, et al. Outreach for annual colorectal cancer screening: a budget impact analysis for community health centers. Am J Prev Med. 2016;50:e54-e61.
24. Oluloro A, Petrik AF, Turner A, et al. Timeliness of colonoscopy after abnormal fecal test results in a safety net practice. J Community Health. 2016;41:864-870.
25. Martin J, Halm EA, Tiro JA, et al. Reasons for lack of diagnostic colonoscopy after positive result on fecal immunochemical test in a safety-net health system. Am J Med. 2017;130:93.e1-93.e7.